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Ablation of galectin-3 induces p27KIP1-dependent
premature senescence without oncogenic stress
S-J Kim1,2, H-W Lee1,3, H Gu Kang1,2, S-H La1,3, Il Ju Choi4, JY Ro5, RS Bresalier6, J Song3 and K-H Chun*,1,2
Premature senescence induced by oncogenic stimuli or tumor suppressor activation plays opposing roles in tumorigenesis.
Here, we propose that galectin-3, a b-galactoside-binding lectin, regulates premature senescence without oncogenic stress.
We detected premature senescence, decreased Skp2, and increased p27KIP1 expression in galectin-3 knockout MEFs and
galectin-3-depleted gastric cancer cells. Interestingly, galectin-3 depletion did not affect other senescence inducers such as
p14ARF, p16INK4A, and p21WAF1/CIP1, suggesting that galectin-3-regulated senescence is p27KIP1 dependent. We demonstrate that
galectin-3 depletion decreases retinoblastoma protein (Rb) phosphorylation (Ser780, Ser807/811), cyclin D1 and CDK4
expression, and E2F1 transcriptional activation. Galectin-3 directly interacts with the cyclin D1/CDK4 complex and promotes
hyperphosphorylation of Rb. It also blocks the inhibition of E2F1 transcription, thereby increasing the expression of Skp2 and
reducing the stability of p27KIP1 to promote the proliferation of gastric cancer cells. Xenograft mice with galectin-3-depleted
gastric cancer cells display tumor growth retardation that is reversed by Skp2 overexpression. Increased expression of galectin-3 is
also associated with the advanced TNM (tumor, lymph node, metastasis) system, clinicopathological stage, and lymph node
metastases. The probability of survival was significantly decreased in gastric cancer patients with galectin-3high p27KIP1-lowcells.
Taken together, our results show that galectin-3 may accelerate gastric tumorigenesis by inhibiting premature senescence.
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Uncontrolled cellular proliferation is a hallmark of tumorigen-
esis that often occurs because of the failure of intrinsic tumor
suppressor mechanisms such as premature senescence.1,2
This process is triggered by the activation of oncogenes,
tumor suppressor genes, or the DNA damage response.
Aberrant oncogene activation (Ras and Myc) or excessive
mitogenic signaling such as growth factor receptor signaling
can induce senescence through two different pathways: the
ARF/p53/p21 pathway or the p16INK4A/pRb pathway. Tumor
suppressor genes such as pRb, PTEN, VHL, and NF1 also
induce cellular senescence by suppressing the oncogenes or
directly controlling the two pathways.3 These senescence
signals induce cells to withdraw from the cell cycle. Such
senescent cells are usually larger, flattened out, and display
increased lysosomal b-galactosidase activity.4
In this study, we demonstrate that galectin-3 inhibits
premature senescence and is therefore involved in gastric
tumorigenesis. Galectin-3, a type of chimeric 31-kDa galacto-
side-binding protein, is involved in cell–cell and cell–matrix
interactions, pro-mRNA splicing, angiogenesis, tumorigen-
esis, and metastases.5–7 It is well established8 that galectin-3
shows widespread distribution among different types of cells
and tissues and is found in the nucleus and cytoplasm. It is
also secreted extracellularly via the nonclassical pathway and
can thus be found on the cell surface or in the extracellular
space. Our research has focused on the functions of nuclear
galectin-3 because its expression is associated with poor
prognosis of cancer therapy and is known to regulate
tumorigenesis by binding transcription factors such as AP-1,
TTF-1, SP-1, and TCF-4.8–10 We knocked down galectin-3
using small interfering RNA (siRNA) in human gastric cancer
cells and observed the induction of premature senescence
and changes in the expression of cell cycle regulators such as
decreased S-phase kinase-associated protein 2 (Skp2) and
increased p27KIP1. Low levels of p27KIP1 are known to affect
tumor progression and indicate poor prognosis of breast,
colorectal, and hematologic malignancies.11–13 The expres-
sion of p27KIP1 is regulated by the ubiquitin system that
involves an SCF (Skp1-cullin-F-box protein) ubiquitin ligase
complex in which Skp2 acts as a specific substrate-recogniz-
ing subunit.14,15 Skp2 plays an oncogenic role through the
promotion of p27KIP1 degradation, and numerous studies
have examined the prognostic significance of Skp2 in human
cancers.16,17 Inactivation of Skp2 cannot induce cellular
senescence, but potentiates oncogenic activation and inacti-
vates tumor suppressor gene-induced cellular senescence.18
Oncogenic stress and Skp2 inactivation-driven senescence
depend on Atf4, p27KIP1, and p21WAF1/CIP1, but not on the
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ARF-p53 pathway. Interestingly, downregulation of galectin-3
reduces Skp2 expression and only induces p27KIP1 expres-
sion. Although p27KIP1 has been implicated in senescence, its
precise role in this process is unclear.
In this study, we prepared galectin-3 knockout (galectin-3 / )
mouse embryonic fibroblasts (MEFs) and galectin-3-depleted
gastric cancer cells and determined that galectin-3 is dependent
on p27KIP1 for the regulation of premature senescence without
oncogenic stress. We used mice xenografted with gastric
cancer cells to examine the gene function in gastric
tumorigenesis. In addition, we analyzed the clinicopathological
correlation between the expression of galectin-3, Skp2, and
p27KIP1 in gastric cancer patients.
Results
Depletion of galectin-3 induces G1 cell cycle arrest in a
p27KIP1-dependent manner. We screened 12 human
gastric cancer cell lines to examine the levels of galectin-3.
We also determined the relationship between the expression
of galectin-3 and the tumorigenicity/metastatic potential of
gastric cancer cell lines. We chose the AGS (high expression
of galectin-3) cell line to attempt galectin-3 depletion and the
SNU-638 (galectin-3 null) cell line for the study of galectin-3
upregulation (Supplementary Figure 1). Treatment of AGS
cells with 10mM galectin-3 siRNA (Gal3 siRNA) for 2 days
reduced cell proliferation by 50% (Figure 1a). Interestingly,
galectin-3 depletion was accompanied by decreased Skp2
and increased p27KIP1 expression. Although the expression
of p16INK4A and p21WAF1/CIP1 remained unchanged, p14ARF
levels were found to decrease slightly (Figure 1b). Galectin-3
depletion reduced Skp2 mRNA but increased p27KIP1 protein
expression without a change in the mRNA expression. This
suggests that galectin-3 regulates the level of p27KIP1 protein
by Skp2-mediated ubiquitin activity (Figure 1c). Moreover,
the depletion of galectin-3 significantly increased the number
of G1 cell cycle-arrested cells and the sub-G1 populations,
whereas co-depletion of galectin-3 and p27KIP1 produced
equivalent proliferation to scRNA control group cell popula-
tions (Figures 1d and e).
Increased premature senescence and decreased cell
proliferation in galectin-3 / MEFs. The growth and
premature senescence of galectin-3 / and wild-type
(galectin-3þ /þ ) MEFs were analyzed using SA-b–galactosi-
dase staining. Galectin-3 / MEFs showed growth retarda-
tion when compared with galectin-3þ /þ MEFs (Figure 2a).
Moreover, 55% of the galectin-3 / MEFs displayed
premature senescence, whereas only 10.8% of the wild-type
(WT) MEFs went through senescence at passage 6
(Figure 2b). A significant decrease in the Skp2 mRNA and
protein levels was observed in the galectin-3þ /þ MEFs.
Although the mRNA level remained unchanged, there
was a detectable increase in the p27KIP1 protein levels in
Figure 1 Inhibition of galectin-3 reduces the proliferation of gastric cancer cells in a Skp2- and p27KIP1-dependent manner. (a) Cell proliferation after silencing of galectin-3
using siRNA transfection with respect to time (1–3 days) and concentration (1–20 nM) in the AGS human gastric cancer cells. The error bars indicate 95% confidence intervals;
*, **Po0.0001 using one-way ANOVA. (b) Detection of the levels of galectin-3, Skp2, p27KIP1, p14ARF, p16INK4A, and p21WAF1/CIP1 after silencing of galectin-3 using siRNA
transfection in the AGS human gastric cancer cells. b-Actin was used as the normalization control. (c) Detection of mRNA and protein expression of galectin-3, p27KIP1, and
Skp2 after transfection with galectin-3 siRNA for 48 h, as analyzed by RT-PCR and immunoblotting, respectively. b-Actin was used as the normalization control. (d and e) After
transfection of AGS cells with galectin-3 siRNA, p27KIP1 siRNA, and co-transfection of AGS cells with both siRNAs (d) the protein expression of galectin-3, p27KIP1, and Skp2
was analyzed by western blotting. b-Actin was used as the normalization control. (e) Cell cycle populations were examined by PI staining. A quantitative graph (left panel) and
histogram (right panel) are generated. Marking of histogram is as follows: M1-SubG1, M2-G1, M3-S, and M4-G2
Galectin-3 inhibits premature senescence
S-J Kim et al
1770
Cell Death and Differentiation
galectin-3 / MEFs. No change in p21WAF1/CIP1 expression
was observed in either of the cell types (Figure 2c). To further
examine the effect of galectin-3 on p27KIP1 expression and
premature senescence, we prepared human foreskin fibro-
blasts and silenced the expression of galectin-3 or p27KIP1
using specific siRNAs (Figure 2d). Depletion of galectin-3
resulted in growth retardation (Figure 2e) and premature
senescence (Figure 2f) in the human foreskin fibroblasts,
whereas additional depletion of p27KIP1 reversed the effect of
galectin-3 on these cells. Thus, galectin-3 appears to inhibit
premature senescence through the inhibition of the expres-
sion of p27KIP1 protein.
Increased premature senescence by inhibition of galectin-3
without oncogenic stress is p27KIP1 dependent, but p53
independent. To examine whether premature senescence
induced by galectin-3 depletion is affected by p53, we
employed two gastric cancer cell lines: AGS (with WT p53)
and SNU-601 (p53 is nonfunctional because of the point
mutation R273L). Upon galectin-3 depletion, both the cell
types exhibited growth retardation and additional p27KIP1
ablation reversed this growth retardation (Figures 3a and c
and supplementary Figures 2a and c). Similarly, premature
senescence, which was accelerated by galectin-3 depletion
in both the cell lines, was rescued by the additional p27KIP1
inhibition (Figures 3b and d and Supplementary Figures 2b
and d). There was no difference in the induction of
premature senescence based on the p53 status, suggesting
that galectin-3 depletion induces senescence in a
p27KIP1-dependent and p53-independent manner. Galectin-3
depletion alone can induce premature senescence in the
gastric cancer cells. Conversely, galectin-3 overexpression
can rescue this galectin-3 knockdown-mediated premature
senescence (Supplementary Figure 3). Taken together,
these results demonstrate that galectin-3 regulates prema-
ture senescence in the gastric cancer cells.
Overexpression of galectin-3 or Skp2 induces a
decrease in p27KIP1 protein expression. When galectin-3
was overexpressed in the galectin-3-null SNU-638 cells, the
expression of Skp2 and p27KIP1 was found to increase and
decrease, respectively; additional Skp2 depletion enhanced
the p27KIP1 expression (Figure 3e). Although cell proliferation
was increased by galectin-3 overexpression, additional Skp2
depletion restored it to the control levels (Figure 3f). Increase
in the G1 cell cycle population induced by Skp2 depletion was
also rescued by galectin-3 overexpression (Figure 3g).
We also prepared an Skp2 overexpression vector and
transiently transfected it into the SNU-638 cells. Increased
p27KIP1 expression resulting from galectin-3 depletion was
significantly diminished by Skp2 overexpression (Figure 4a).
Although cell proliferation increased by Skp2 overexpression,
it was not significantly affected by galectin-3 depletion
(Figure 4b). An increase in the G1 cell cycle population
Figure 2 Decreased cell proliferation and increased premature senescence in galectin-3 knockout mouse embryonic fibroblasts (MEFs) and galectin-3-depleted human
skin fibroblasts. (a) Expression levels of galectin-3 in galectin-3 / and galectin-3þ /þ MEFs were analyzed by western blotting (upper panel). Galectin-3 / and galectin-
3þ /þ MEFs were stained with crystal violet (lower panel), and the graph shows the percentage of cells in the microscopic fields (right panel). The error bars indicate 95%
confidence intervals; *P¼ 0.0397 using the two-sided t-test. (b) Cell lysates of galectin-3 / and galectin-3þ /þ MEFs were prepared and analyzed by RT-PCR using
primers specific for p27KIP1, Skp2, and galectin-3. GAPDH served as the normalization control. Protein levels were also detected using antibodies against p27KIP1,
p21WAF1/CIP1, Skp2, and galectin-3 by western blotting. b-Actin was used as the normalization control. (c) Premature senescence was induced in galectin-3 / MEFs.
Galectin-3 / and galectin-3þ /þ MEFs were stained for b-galactosidase activity. The graph shows the percentage of b-galactosidase-positive cells (right panel). The error
bars indicate 95% confidence intervals; *Po0.0001 using the two-sided t-test. The scale bar indicates 100mm. (d) After 48 h of transfection with control siRNA, galectin-3
siRNA, p27KIP1 siRNA, and both siRNAs in human skin fibroblasts, the cells were stained with crystal violet. (e) Cell lysates were subjected to western blotting using the
indicated antibodies. (f) Premature senescence was detected by b-galactosidase activity. The graph shows the percentage of b-galactosidase-positive cells (right panel).
The error bars indicate 95% confidence intervals; *Po0.0001 and **P¼ 0.0003 using the two-sided t-test
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induced by galectin-3 depletion was also compensated for by
Skp2 overexpression (Figure 4c). These data suggest that
overexpression of both galectin-3 and Skp2 results in reduced
p27KIP1 expression and cell cycle progression.
Depletion of Skp2 induces premature senescence
through an increase in p27KIP1 protein levels. As the
ablation of galectin-3 induces premature senescence through
a decrease in Skp2, we examined Skp2-dependent p27KIP1
expression and premature senescence in the gastric cancer
cells. When Skp2 was depleted, p27KIP1 expression increased
(Figure 4d) and cell proliferation decreased (Figure 4e and
Supplementary Figure 4a). However, this decrease was
abrogated by p27KIP1 depletion. The increase in premature
senescence (Figure 4f and Supplementary Figure 4b) and the
G1 cell cycle population (Figure 4g and Supplementary
Figure 4c) caused by Skp2 depletion was restored to the
control levels by p27KIP1 depletion. This suggests that
galectin-3-regulated Skp2 is important for the regulation of
p27KIP1 expression for inducing premature senescence and
inhibiting the proliferation of gastric cancer cells.
Inhibition of galectin-3 reduces phosphorylation of
retinoblastoma protein (Rb) and expression levels of
cyclin D1 and CDK4. In order to determine how galectin-3
regulates Skp2 and p27KIP1 expression, we examined the
expression of the G1/S phase-related genes such as Rb,
E2F1, cyclin D1, and CDK4 (Figure 5). Galectin-3 depletion
drastically decreased the phosphorylated forms of Rb (Ser
780, Ser 807/811) and the expression of cyclin D1 and
CDK4, whereas total Rb and E2F1 levels remained
unchanged (Figure 5a and Supplementary Figure 5a).
Interestingly, PTEN was slightly increased and k-Ras and
c-Myc were decreased by galectin-3 depletion, suggesting
that tumor suppressors or oncogenic stresses are not
involved in galectin-3-induced premature senescence
(Figure 5a). We also determined the cellular localization of
these proteins (Supplementary Figure 6a). Galectin-3 deple-
tion decreased the phosphorylated forms of Rb in the
nucleus and cytosol. The nuclear E2F1 levels remained
unchanged, whereas an increased Rb level was evident only
in the nucleus. The nuclear levels of cyclin D1 and CDK4
were decreased. In addition, Skp2 protein levels decreased
in both the nucleus and cytosol, whereas p27KIP1 level
increased with galectin-3 depletion.
Furthermore, the overexpression of galectin-3 increased
the levels of phosphorylated Rb (Ser 780, Ser 807/811) and
Skp2, and decreased p27KIP1 expression (Figure 5b and
Supplementary Figure 5b). The expression of cyclin D1,
CDK4, k-Ras, and c-myc increased, whereas that of PTEN
was decreased by galectin-3 overexpression. We also
detected the cellular localization of these proteins during
Figure 3 Increased premature senescence caused by the inhibition of galectin-3 is p27KIP1 dependent, but p53 independent. (a) After 48 h of transfection with control
siRNA, galectin-3 siRNA, p27KIP1siRNA, and both siRNAs in the (a and b) AGS cells and (c and d) SNU601 cells, (a) cell proliferation was evaluated. The error bars indicates
95% confidence intervals; * Po0.0001 and **P¼ 0.0047 using a two-sided t-test. (b) Premature senescence was detected by b-galactosidase activity. The graph shows the
percentage of b-galactosidase-positive cells. The error bars indicate 95% confidence intervals; *Po0.0001 and **Po0.0001 using the two-sided t-test. (c) Cell proliferation
was determined and the data were presented as a histogram. The error bars indicate 95% confidence intervals; *Po0.0001 and **P¼ 0.0139 using the two-sided t-test.
(d) Premature senescence was analyzed by determining the b-galactosidase activity. The graph shows the percentage of b-galactosidase-positive cells. The error bars
indicate 95% confidence intervals; *P¼ 0.0008 and **P¼ 0.0013 using the two-sided t-test. (e–g) After transfection with the galectin-3 plasmids, Skp2 siRNA was additionally
transfected into the SNU-638 cells. (e) Expression of the indicated proteins was detected by western blotting. (f) Cell proliferation and (g) cell cycle population analyses were
performed by Ez-Cytox assay and PI staining, respectively. The error bars indicate 95% confidence intervals; *P¼ 0.0005 and **P¼ 0.0067 using the two-sided t-test
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galectin-3 overexpression using the nuclear isolation assay
(Supplementary Figure 6b). Taken together, depletion and
overexpression of galectin-3 induce a contrasting pattern of
expression of these proteins in the nucleus and cytosol
(Supplementary Figures 6a and b).
Galectin-3 induces Rb phosphorylation by cyclin D1 and
CDK4. Rb phosphorylation induced by galectin-3 overex-
pression was diminished by the depletion of cyclin D1 and
CDK4, without any changes in the Rb expression (Figure 5c).
Depletion of cyclin D1 and CDK4 changed the expression of
Skp2 and p27KIP1. We prepared several domains of the
amino acid sequences of galectin-3 and transiently over-
expressed them in the SNU-638 gastric cancer cells
(Figure 5d). Although the full-length galectin-3 and 1–110
amino acids (aa) increased Rb phosphorylation and the
expression of cyclin D1 and CDK4, the 33–250, 63–250, and
111–250 aa of galectin-3 did not affect the expression
of these proteins (Figure 5e). This indicates that 1–32 aa of
galectin-3 affect Rb phosphorylation and the expression of
cyclin D1 and CDK4.
The N-terminal domain of galectin-3 directly interacts
with Rb and the cyclin D1/CDK4 complex. The fact that
1–32 aa of galectin-3 affect Rb phosphorylation prompted
us to speculate that the two proteins may physically bind to
each other. Using immunoprecipitation, we detected a
strong interaction between galectin-3 and Rb and no
interaction between galectin-3 and E2F1 (Figure 6a). The
cyclin D1/CDK4 complex was also found to interact with
galectin-3, suggesting that galectin-3 mediates the phospho-
rylation of Rb and its interaction with the cyclin D1/CDK4
complex. Overexpression of the full-length galectin-3
and the absence of the carbohydrate-recognition-binding
domain (CRD) domain (i.e., 1–110 aa) result in the
interaction of galectin-3 with Rb, cyclin D1, and CDK4
(Figure 6b) whereas the overexpression of other domains,
that is, in the absence of the N-terminal tail (33–250,
63–250, or 111–250 aa), inhibits the interaction of galectin-3
with these proteins.
Interestingly, the interaction between Rb and E2F1 was
strongly detected in the absence of galectin-3, although Rb
did not interact with cyclin D1 and CDK4 (Supplementary
Figure 7a). The interaction between p27KIP1, cyclin D1, and
CDK4 was enhanced by galectin-3 depletion. In addition,
overexpression of galectin-3 reduced the interaction between
Rb and E2F1 and induced the interaction between Rb and
the cyclin D1/CDK4 complex (Supplementary Figure 7b).
Figure 4 Inhibition of Skp2 reduces cell proliferation and induces premature senescence through an increase of p27KIP1 protein expression. (a–c) After transfection with
the Skp2 plasmids, galectin-3 siRNA was additionally transfected into the AGS cells. (a) Protein expression, (b) cell proliferation, and (c) cell cycle population analyses were
performed by western blotting, Ez-Cytox assay, and PI staining, respectively. The error bars indicate 95% confidence intervals; *P¼ 0.0094 using the two-sided t-test.
AGS cells were transfected with control siRNA, Skp2 siRNA, p27KIP1siRNA, or both siRNAs for 48 h; (d) the protein expression was analyzed by western blotting and
(e) cell proliferation was evaluated and the data are presented as a histogram. The error bars indicate 95% confidence intervals; *P¼ 0.0005 and **P¼ 0.0156 using the
two-sided t-test. (f) Premature senescence was detected by b-galactosidase activity. The graph shows the percentage of b-galactosidase-positive cells. The error bars
indicate 95% confidence intervals; *P¼ 0.0013 and **P¼ 0.0017 using the two-sided t-test. (g) The cell cycle populations were analyzed by PI staining
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The interaction between p27KIP1, cyclin D1, and CDK4 was
also decreased by galectin-3 overexpression.
Galectin-3 releases E2F1 to promote its transcriptional
activity in a cyclin D1- and CDK4-dependent manner.
We investigated the E2F1 binding motif in the Skp2 promoter
by performing the chromatin immunoprecipitation (ChIP)
assay (Figure 6c). Galectin-3 depletion was found to
suppress the binding of E2F1 to this region. The E2F1
luciferase reporter activity was found to significantly increase
by the overexpression of the full-length galectin-3 and the
absence of the CRD domain (1–110 aa), but remained
unchanged by overexpression of the other domains of
galectin-3 (absence of the N-terminal tail of galectin-3
(33–250, 63–250, or 111–250 aa); Figure 6d). Moreover,
the E2F1 luciferase activity was decreased by the depletion
of galectin-3, cyclin D1, or CDK4 (Figure 6e). Increased
E2F1 luciferase activity by galectin-3 overexpression was
reversed by cyclin D1 or CDK4 (Figure 6f).
Taken together, our results suggest that galectin-3 directly
interacts with Rb and the cyclin D1/CDK4 complex that in turn
induces Rb phosphorylation. In addition, galectin-3 releases
E2F1 and promotes its transcriptional activity. Increased Skp2
decreases the stability of p27KIP1, thereby promoting cell cycle
progression and inhibiting premature senescence (Figure 7d).
Galectin-3 depletion reduces tumor burden that is
reversed by the overexpression of Skp2 in mice
xenografted with AGS cancer cells. We prepared stable
galectin-3-depleted gastric cancer cells with Skp2 over-
expression (Figure 7a) to detect the in vivo effects of
galectin-3 and Skp2 on gastric tumorigenesis in mice. The
gastric tumor size was reduced in galectin-3-depleted
xenografted mice; however, Skp2 overexpression restored
the tumor growth to the control levels (Figures 7b and c).
Immunohistochemical analysis revealed that increased
p27KIP1 expression and decreased Skp2 expression were
observed in the galectin-3-depleted tumor sections, whereas
Skp2 overexpression reversed the decrease of p27KIP1
expression (Supplementary Figure 8).
Clinicopathological analysis of galectin-3 expression in
malignant tissues of gastric cancer patients. We
analyzed the expression of galectin-3 in the malignant
tissues of 50 gastric cancer patients using tissue microarrays
(Supplementary Tables 1 and 2) and found that galectin-3
Figure 5 Inhibition or overexpression of galectin-3 regulates the phosphorylation of Rb and expression levels of cyclin D1 and CDK4. (a) Detection of protein levels of
ppRb (at Ser 780 and Ser 807/811), Rb, E2F1, cyclin D1, and CDK4 after the depletion of galectin-3 using siRNA transfection in the AGS human gastric cancer cells.
(b) Detection of the protein levels of galectin-3, Skp2, Rb, ppRb (at Ser 780 and Ser 807/811), and p27KIP1 by western blot analysis in SNU-638 cells infected with a lentiviral
construct containing galectin-3 or LacZ as the negative control. (c) Detection of the levels of galectin-3, Skp2, Rb, ppRb (at Ser 780 and Ser 807/811), and p27KIP1 by western
blot analysis after transfection of cyclin D1 and CDK4 in SNU-638 cells infected with the constructs in (b). (d) Schematic model of Flag-galectin-3 domain (1–250 aa as the full
length; 1–110 aa as the N-terminal tail; and 33–250, 63–250, and 111–250 aa as the CRD). (e) Detection of the levels of galectin-3, Skp2, Rb, ppRb (at Ser 780 and Ser
807/811), and p27KIP1 by western blot analysis after transfection of the galectin-3 domains in SNU-638 cells. b-Actin was used as the normalization control
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expression was statistically correlated with increasing
T classification (P¼ 0.0262), lymph node metastases
(P¼ 0.001), and increasing TNM (tumor, node, metastasis)
stage (P¼ 0.0053). This suggests that increased galectin-3
expression in gastric cancer tissues may indicate poor
prognosis.
Positive correlation between the expression of galectin-3
and Skp2 and the significantly decreased probability
of survival of gastric cancer patients with tumors
showing high galectin-3 and low p27KIP1 expression.
Initially, we found that compared with normal gastric tissues
in 52 gastric cancer patients, the expression of both galectin-3
and Skp2 mRNA was increased in the malignant gastric
tissues (P¼ 0.0001 and P¼ 0.0034, respectively; two-sided
w2-test) (Figure 8a and Supplementary Figure 9). Compared
with their normal counterparts, malignant tissues showed a
76.9% and 73.1% increase in the expression of galectin-3
and Skp2, respectively (Supplementary Figure 9b), with a
combined increase of 77.5%.
Using immunohistochemical analysis of the tissue micro-
arrays, the colocalization of galectin-3 and Skp2 and the
inverse relationship between galectin-3 and p27KIP1 expres-
sion were also evident in the malignant tissues of the gastric
cancer patients (Figure 8c). The probability of survival of
patients whose tumors showed high expression of galectin-3
and low expression of p27KIP1 (n¼ 24/52) was significantly
lower than that of patients whose tumors showed low
expression of galectin-3 and high expression of p27KIP1
(n¼ 6/52) (P¼ 0.0417), as determined by immunohistochem-
ical analysis (Figure 8b). These data support the notion that
galectin-3 promotes gastric tumorigenesis by regulating the
expression of Skp2 and the stability of p27KIP1.
Discussion
Premature senescence involves the loss of proliferative ability
and has been extensively studied with respect to tumori-
genesis. It depends on a number of signaling pathways that
include tumor suppressors and oncogenes, such as the
Figure 6 Galectin-3 directly interacts with Rb and regulates the transcriptional activity of E2F1. (a) Immunoprecipitation was performed with antibodies against galectin-3
and Rb to detect the interactions of galectin-3 with E2F1, Rb, cyclin D1, and CDK4 in the AGS cells. Whole cell lysate was used as the positive control. (b) Immunoprecipitation
with Flag-galectin-3 domains, Cyclin D1, CDK4, and Rb using transfection of the galectin-3 domains in SNU-638 cells. (c) Schematic model of the interaction of the Skp2
promoter with the E2F1 binding site. ChIP primers were prepared to detect the E2F1 binding site ( 42 to  35) from  95 to þ 135. The ChIP assay was performed using
antibodies against galectin-3, Rb, and E2F1 in scRNA- and galectin-3 siRNA-transfected AGS cells. A PCR primer for the Skp2 promoter was used to detect promoter
fragments in the immunoprecipitates. The input lane with total genomic DNA was used as a control for the PCR reaction. (d–f) Detection of luciferase activity after transfection
of (d) SNU638 cells with an E2F1 consensus plasmid and galectin-3 domains for 48 h, (e) AGS cells with siRNA targeting galectin-3, Cyclin D1, and CDK4, or LacZ as a
negative control for 48 h, and (f) galectin-3-overexpressing SNU638 cells with siRNA targeting Cyclin D1 and CDK4 for 48 h. The cells were transfected with 1mg of the E2F1
consensus plasmid. The error bars indicate 95% confidence intervals; *Po0.0001 using a two-sided t-test. Three independent experiments were performed
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p16INK4a/Rb pathway, the ARF/p53/p21WAF1/Cip1 pathway,
and the PTEN/p27Kip1 pathway.1,19 Oncogenic stress or DNA
damage can trigger premature senescence. When the stress
exceeds a threshold level, the expression of p15 and p16INK4a
increases to inhibit cyclin D1-CDK4/6; subsequently, depho-
sphorylated Rb controls the induction of senescence by
repressing the transcriptional activity of E2F1.20 ARF is also
induced by oncogenic stress and inhibits MDM2, thereby
activating p53 and p21WAF1/Cip1.21 In case of the activation of
a tumor suppressor, PTEN dephosphorylates AKT and
consequently stabilizes p27Kip1.19 Collectively, the induction
of cell cycle regulators by oncogenes or tumor suppressors
plays a critical role in senescence.
Previously, we showed that galectin-3 regulates the cell
cycle in gastric cancer;22 however, the role of galectin-3 in
premature senescence is unknown. We demonstrated that
galectin-3 depletion caused retarded growth and earlier
induction of cellular senescence in galectin-3 / MEFs than
in galectin-3þ /þ MEFs. Galectin-3 depletion also induces
premature senescence in gastric cancer cells. It is worth
noting that induction of premature senescence occurs with
galectin-3 depletion alone. This finding was unexpected,
because galectin-3 is an activator of oncogenes such as Ras
or Myc23,24 and Akt,25 and galectin-3 increases the levels of
p21WAF1/Cip1 by direct interaction and stabilization.26 We also
confirmed that galectin-3 depletion reduced k-Ras and c-Myc.
Therefore, the mechanism by which galectin-3 regulates
premature senescence remains unclear.
In this study, we determined themechanism of the induction
of premature senescence by galectin-3 depletion without
oncogenic stimuli. This phenomenon is mediated by galectin-
3-induced Rb hyperphosphorylation that is in turn caused by
the direct interaction of galectin-3 and the cyclin D1/CDK4
complex. Rb phosphorylation plays an important role in the
regulation of Rb activities by CDK complexes.27 Hypopho-
sphorylated Rb actively inhibits cell cycle progression from the
G1 to S phase and also induces premature senescence.
28 We
show that galectin-3 depletion reduces the expression of both
cyclin D1 and CDK4. Previous reports also indicate that
galectin-3 augments cyclin D1 expression.29 Therefore, we
suggest that galectin-3 increases both the expression and
activation of the cyclin D1/CDK4 complex and consequently
leads to hyperphosphorylation of Rb.
The Rb tumor suppressor gene is inactivated in many
cancers, including gastric cancer.30,31 Rb affects tumor
progression by regulating the cell cycle, differentiation, and
apoptosis. These functions are mediated by the interaction of
Rb with other cellular proteins, especially the E2F transcrip-
tion factors.27,32 When galectin-3 hyperphosphorylates Rb
through the cyclin D1/CDK4 complex, E2F1 is released from
Rb and initiates its transcriptional functions. The direct
interaction of galectin-3 with E2F1, a transcription factor of
Figure 7 Galectin-3 depletion reduces the tumor burden in gastric cancer cell-xenografted mice and these effects are reversed by overexpression of skp2.
(a–d) Lentiviruses expressing galectin-3 shRNA and overexpressing Skp2 were employed to produce stable AGS cell lines. Lentivirus expressing shRNA targeting LacZ was
used as a control. Mice (n¼ 5 per group) were inoculated subcutaneously into both flanks with 106 cells of each of the AGS cell lines. (a) Skp2 overexpression and galectin-3
depletion were confirmed by western blot analysis. (b) Tumor formation was observed 30 days after inoculation. (c) Tumor formation was quantified by measuring the tumor
volume 10 days after inoculation (n¼ 5). The error bars indicate 95% confidence intervals; *P¼ 0.001 and **P¼ 0.0015 using two-sided t-test. All statistical tests were two
sided. (d) Schematic model of galectin-3-dependent promotion of tumor progression and premature senescence. Galectin-3 interacts with Cyclin D1, CDK4, and Rb and
blocks the inhibition of E2F1 transcription. This increases the expression of Skp2 and reduces the stability of p27KIP1 to promote the proliferation of gastric cancer cells.
After galectin-3 depletion, Rb interacts with E2F1 to block the transcriptional activity of E2F1, suppress Skp2 expression, and increase the stability of p27KIP1. This results in the
suppression of the proliferation of gastric cancer cells and in the induction of premature cellular senescence
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Skp2,15 is not supported by our data. A direct interaction
between Rb and galectin-3 activated E2F1 to generate skp2.
We have shown that galectin-3 regulates the expression of
Skp2 and p27KIP1 during the induction of premature senes-
cence. Although Skp2/p27KIP1 is known to be involved in
cellular senescence, it is usually accompanied by the
activation of p16INK4a or the tumor suppressor PTEN. Here,
galectin-3 directly regulates the expression of Skp2 and
p27KIP1 without activating p16INK4a or PTEN. This effect
seems to be organ specific, and these results are concordant
with the clinicopathological data from gastric cancer patients.
The levels of galectin-3 were proportional to the progression
of the TNM stage and lymph node metastasis, providing
strong evidence for the involvement of galectin-3 in the
progression and metastasis of gastric cancer. Interestingly,
premature senescence is caused by the stabilization of
p27KIP1 in the absence of galectin-3. In gastric cancer, loss
of p27KIP1 is associated with advanced stages and decreased
survival.33,34 We also demonstrate poor survival in gastric
cancer patients with high expression of galectin-3 and low
expression of p27KIP1. Although galectin-3 is known to
regulate p27KIP1 expression,35 the underlying molecular
mechanism remains unexplored. Here, we demonstrate that
galectin-3 increases the expression of Skp2 and induces
degradation of p27KIP1 protein, without influencing p27KIP1
mRNA levels. Skp2 is known to promote gastric tumorigen-
esis17,36 and block premature senescence.18,37 We have
demonstrated a parallel expression of galectin-3 and Skp2 in
gastric cancer, and our data suggest a molecular mechanism
that links galectin-3 and Skp2 to decreased expression of
p27KIP1 and prevention of senescence.
Taken together, our data suggest that galectin-3 prevents
premature senescence and accelerates gastric tumori-
genesis. Thus, inhibition of galectin-3 may have therapeutic
implications in the treatment of gastric cancer.
Materials and Methods
Cell culture. Twelve human gastric cancer cell lines (AGS, MKN28, YCC-2,
KATOIII, SNU-1, SNU-5, SNU-16, SNU-216, SNU-601, SNU-638, SNU-668,
and SNU-719) obtained from the Korea Cell Line Bank (KCLB, Seoul, Korea) were
Figure 8 Positive association between galectin-3 and Skp2 expression and negative association between galectin-3 and p27KIP1 expression is found in malignant tissues
of gastric cancer patients. (a) The correlation between the mRNA expression of galectin-3 and Skp2 in the malignant tissues of 52 gastric cancer patients. The mRNA
expression was detected by RT-PCR and quantified by an NIH ImageJ analyzer. GAPDH and b-actin were used as normalization controls. (b) The probability of survival of
gastric cancer patients whose tumors show high galectin-3 and low p27KIP1 levels is (red line) compared with that of gastric cancer patients whose tumors show low galectin-3
and high p27KIP1 levels (blue line) using Kaplan–Meyer analysis. Statistical analysis is described in the Materials and Methods section. (c) Protein expression of galectin-3,
Skp2, and p27KIP1 in the malignant tissues of gastric cancer patients, as shown by immunohistochemical staining (brown) with hematoxylin and eosin (H&E). The stained
tissue samples were observed using an inverted light microscope. Magnification:  200 (top) and  400 (bottom)
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cultured in RPMI-1640 medium supplemented with 5% fetal bovine serum (FBS)
and 1% antibiotics. The phenotypes of these cell lines have been authenticated by
the KCLB.
Preparation of galectin-3 KO MEFs. C57BL/6 mice with a galectin-3-
knockout (KO) allele (male and female mice, homozygous  / ), were
kindly provided by Dr. FT Liu (UC Davis, CA, USA).38 Female and male N6
galectin-3þ / mice were crossed to obtain galectin-3þ /þ and galectin-3 /
MEFs. The preparation of MEFs was performed as described previously.39
SA-b-galactosidase assay. The b-galactosidase assay for senescence
was performed using a Senescence Detection Kit (#K320-250, BioVision,
Mountain View, CA, USA), as previously described.21 Briefly, cells were plated
in 60-mm dishes, cultured for 2–3 days, washed once with phosphate-buffered
saline (PBS), and fixed with a fixation solution for 15 min at room temperature.
Cells were washed twice with PBS and incubated with the staining solution
overnight at 371C before microscopic analysis.
RNA isolation and reverse transcription-PCR (RT-PCR). RNA
isolation was performed with the TRIzol Reagent (Invitrogen, Carlsbad, CA, USA)
according to the manufacturer’s instructions. Subsequently, RT-PCR using a
Reverse Transcription system (Promega, Madison, WI, USA) was performed as
previously described.40 The following primers were used: Skp2, forward
50-CGTGTACAGCACATGGAACCT-30 and reverse 50-GGGCAAATTCAGAGAA
TCCA-30; LGALS3, forward 50-ATGGCAGACAATTTTTCGCTCC-30 and reverse
50-ATGTCACCAGAAATTCCCAGT T-30; p27KIP1, forward 50-AGATGTCAAACGT
GCGAGTG-30 and reverse 50-TCTCTGCAGTGCTTCTCCAA-30; b-actin, forward
50-AGCCTCGCCTTTGCCGA-30 and reverse 50-CTGGTGCCTGGGGCG-30; and
GAPDH, forward 50-GGCTGCTTTTAACTCTGGTA-30 and reverse 50-ACTTGAT
TTTGGAGGGATCT-30. PCR was performed according to the Ex-Taq manual
(TaKaRa, Shiga, Japan).
Galectin-3 overexpression: construction of vectors and
infection. A galectin-3 overexpression vector (pcDNA3.1/NT-GFP-galectin-3)
and lentiviral vectors containing galectin-3 overexpression were constructed by
inserting the galectin-3 gene into the lentiviral vector pLL3.7, as described
previously.5,24
Western blot analysis and immunoprecipitation. Western blotting
was performed using anti-galectin-3, anti-Rb, anti-phospho-Rb (Ser 807/811)
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-SKP2, anti-p27KIP1, anti-
p21WAF1/CIP1, anti-p15INK4B, anti-cyclin A, anti-cyclin D1, anti-CDK4, anti-E2F1,
anti-GAPDH, and anti-lamin A/C antibodies (Cell Signaling, Danvers, MA, USA).
The normalization control was anti-b-actin (Sigma, St. Louis, MO, USA).
Immunoprecipitation was carried out with A/G agarose beads coated with
anti-galectin-3 and anti-Rb (Santa Cruz Biotechnology) antibodies. The proteins
were detected by western blot analysis using antibodies against anti-galectin-3,
anti-Rb, and anti-E2F1. Mouse/rabbit IgG (Santa Cruz Biotechnology) was used
as a negative control.41
Luciferase assay. The E2F1 luciferase reporter plasmid under the control of 4
E2F1 consensus and negative control SP1 plasmids as a 3x SP1 consensus were
transfected in galectin-3-depleted or galectin-3-overexpressing cells using the
Lipofectamine 2000 Reagent (Invitrogen) as described previously.42 After 30–40 h,
the cells were harvested and the luciferase activity was estimated using a Luciferase
Assay System (Promega). The results were normalized to b-galactosidase.
ChIP assay. ChIP assays were performed using a ChIP Assay Kit (Upstate,
Temecula, CA, USA), according to the manufacturer’s instructions. Anti-galectin-3,
anti-Rb, anti-E2F1, and rabbit IgG antibodies were used to immunoprecipitate the
DNA-containing complexes. We prepared a primer pair that anneals to E2F1 in the
SKP2 promoter-binding sites: SKP2 promoter ( 95) 50-CTCCCCGCCTACC
CCGTGG-30; SKP2 promoter (þ 135) 50-CAGACCCGCTAAGCCTAGCAACG-30;
and GAPDH 50-AGCTCAGGCCTCAAGACCTT-30 and 50-AAGAAGATGCGGCT
GACTGT-30 as the normalization control. PCR was performed according to the
Ex-Taq manual (TaKaRa).
Fractionation of cellular extracts. Nuclear and cytoplasmic extracts
were prepared from AGS and SNU638 cells after treatment with galectin-3 siRNA
and galectin-3 overexpression vectors. The experiments were performed as
described previously.5
Crystal violet staining. Cells were transfected with 20 nM of galectin-3,
Skp2, or p27KIP1 siRNA by a reverse transfection method using Lipofectamine
RNAiMax. For crystal violet staining, cells were plated onto 12-well culture dishes
and stained with crystal violet at 2 days after Galectin-3, skp2, or p27KIP1 siRNA
transfection.
Cell proliferation and cell cycle analysis. Inhibition of cell proliferation
by galectin-3, Skp2, or p27KIP1 siRNA treatment was evaluated using Ez-Cytox
Assay Kits. AGS and SNU601 cells were plated in 96-well culture plates (3 103
cells per well). After incubation for 24 h, the cells were treated with 20 nM of
Galectin-3, Skp2, or p27KIP1 siRNA for 48 h. Highly sensitive water-soluble
tetrazolium salt (WST) solution (Daeil, Seoul, Korea; the working of the WST
solution is based on the cleavage of the tetrazolium salt into a water-soluble
formazan by the succinate-tetrazolium reductase system that belongs to the
respiratory chain of mitochondria. It is active only in viable cells) was subsequently
added to each well. After 1–3 h of additional incubation, the plate was shaken
gently. The absorbance was measured on an ELISA reader at a wavelength of
450 nm. In addition, cell cycle distribution after galectin-3, Skp2, and p27KIP1
siRNA treatment was measured by PI staining using FACS.
Preparation of galectin-3-depleted AGS gastric cancer cells for
xenografting into mice. All the animal experiments were approved by the
Institutional Review Board of the Yonsei University College of Medicine and were
performed in specific pathogen-free facilities in accordance with the Guidelines for
the Care and Use of Laboratory Animals of the University (2013-0018). The
preparation of xenograft mice was performed as described previously.43
Microarray analyses of human gastric cancer tissue. For
immunohistochemical analysis, biopsy specimens from the core tissue (2 mm in
diameter) were obtained from individual paraffin-embedded gastric carcinoma
tissues (donor blocks) and arranged in new recipient paraffin blocks (tissue array
blocks) using a trephine apparatus (SuperBioChips Laboratories, Seoul, Korea).
Immunohistochemical analysis of galectin-3 and p27KIP1 was performed as
described previously.44,45
Preparation of frozen tissues from gastric cancer patients. Two
pairs of biopsy specimens (2 mm in diameter) were obtained from 52 patients with
gastric adenocarcinoma during diagnostic endoscopic submucosal dissection.
Immediately after biopsy, these tissue samples were frozen in liquid nitrogen and
stored in a deep freezer at  70 1C until further use. All the participants provided
written informed consent. All the experiments were approved by the Institutional
Review Board of the National Cancer Center (approval number NCCNSH 03-024).
Statistical analyses. We employed w2-tests to evaluate the relationship
between the levels of galectin-3 and p27KIP1 in the tissues of the gastric cancer
patients. Two tumors per mouse were obtained and the mean tumor volume per
mouse was analyzed. Unpaired t-tests were used to analyze the mean tumor
volume in xenograft mice. All the statistical tests are two sided, and the values are
expressed as the mean with 95% confidence intervals (CI). The P-values of
o0.05 were considered statistically significant. Statistical analyses were
performed using GraphPad Prism software (version 6; GraphPad Software Inc.,
La Jolla, CA, USA).
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